A case-control association study and family-based expression analysis of the bipolar disorder candidate gene PI4K2B

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.jpsychires.2009.05.004

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Psychiatric Research

Publisher Rights Statement:
Available under Open Access

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
A case-control association study and family-based expression analysis of the bipolar disorder candidate gene PI4K2B

Lorna M. Houlihan, Andrea Christoforou, Margaret I. Arbuckle, Helen S. Torrance, Susan M. Anderson, Walter J. Muir, David J. Porteous, Douglas H. Blackwood, Kathryn L. Evans

ABSTRACT

Bipolar disorder, schizophrenia and recurrent major depression are complex psychiatric illnesses with a substantial, yet unknown genetic component. Linkage of bipolar disorder and recurrent major depression with markers on chromosome 4p15–p16 has been identified in a large Scottish family and three smaller families. Analysis of haplotypes in the four chromosome 4p-linked families, identified two regions, each shared by three of the four families, which are also supported by a case-control association study. The candidate gene phosphatidylinositol 4-kinase type-II beta (PI4K2B) lies within one of these regions. PI4K2B is a strong functional candidate as it is a member of the phosphatidylinositol pathway, which is targeted by lithium for therapeutic effect in bipolar disorder. Two approaches were undertaken to test the PI4K2B candidate gene as a susceptibility factor for psychiatric illness. First, a case-control association study, using tagging SNPs from the PI4K2B genomic region, in bipolar disorder (n = 368), schizophrenia (n = 386) and controls (n = 458) showed association with a two-marker haplotype in schizophrenia but not bipolar disorder (rs10939038 and rs17408391, global P = 0.005, permuted global P = 0.039). Second, expression studies at the allele-specific mRNA and protein level using lymphoblastoid cell lines from members of the large Scottish family, which showed linkage to 4p15–p16 in bipolar disorder and recurrent major depression, showed no difference in expression differences between affected and non-affected family members. There is no evidence to suggest that PI4K2B is contributing to bipolar disorder in this family but a role for this gene in schizophrenia has not been excluded.

© 2009 Elsevier Ltd. All rights reserved.

1. Objectives

Genetic evidence for psychiatric illness, including bipolar disorder, schizophrenia and related phenotypes to chromosome 4p15–p16, has been established in linkage, population and affected individual studies as detailed previously (Le Hellard et al., 2007). Haplotype analysis of chromosome 4p15–p16 using four families with linkage to that region, highlighted two areas in the 20 Mb linked region, where three of the four linkage regions overlap, namely region B and region D (Le Hellard et al., 2007). These regions have been supported by association analysis in the Scottish population (Christoforou et al., 2007). Region D appeared an attractive region for further study because of the strength of the linkage evidence from a Welsh family with schizophrenia and schizoaffective disorder (LOD 2, (Asherson et al., 1998)) and a large family from the United States of Ashkenazi Jewish origin with major mental illness including bipolar disorder and schizophrenia (LOD 3.2, (Detera-Wadleigh et al., 1999)). Of the 13 known genes in region D (Le Hellard et al., 2007), PI4K2B has the strongest case as a candidate gene from biological and neuropharmacological evidence. In addition, the aforementioned association study identified SNP rs10939038, which lies in the same linkage disequilibrium (LD) block as PI4K2B, as a potentially important variant in schizophrenia cases (allele P = 0.006, odds ratio (OR) = 1.314, 95%C: 1.08–1.59) (Christoforou et al., 2007).

PI4K2B is a phosphatidylinositol 4-kinase and a member of the phosphoinositide (PI) signal transduction pathway. Its primary function is the phosphorylation of phosphatidylinositol to generate phosphatidylinositol 4-phosphate (Balla et al., 2002; Wei et al., 2002). The PI signalling pathway is a target for the mood stabilising drugs, lithium and sodium valproate (Berridge et al., 1989; Farmer et al., 2002; Kato, 2007).

This study examined PI4K2B as a possible genetic risk factor in bipolar disorder or schizophrenia, by two approaches. First, a case-control association study tested association of additional markers in the PI4K2B region in 368 cases with bipolar disorder, 386 cases with schizophrenia and 458 controls from the Scottish population.
population. Second, RNA and protein expression analysis of PI4K2B was conducted with lymphoblastoid cell lines from members of the large Scottish family, which showed linkage to the chromosome 4p15–p16 region (Blackwood et al., 1996).

2. Materials and methods

2.1. Case-control association study

2.1.1. Sample

The cohort consisted of DNA from individuals with bipolar disorder (368: 160 males and 208 females), schizophrenia (386: 276 males and 110 females) and controls (458; 237 males, 218 females and three unknown). Details of this sample have been previously reported (Christoforou et al., 2007). The study was approved by the Multi-Centre Research Ethics Committee for Scotland. The sample comprised individuals contacted through the inpatient and outpatient services of hospitals in South East Scotland. Diagnoses according to DSM-IV criteria were based on information from an interview with the patient using the Schedule for Affective Disorders and Schizophrenia-Life time version (SADS-L) were reached by consensus between two trained psychiatrists. Controls from the same region were recruited through the South of Scotland Blood Transfusion Service and from hospital staff. Control subjects were drawn from the same population in South East and South Central Scotland. The majority (>80%) were recruited through the Scottish National Blood Transfusion service. Although the blood donors were not screened by interview for personal or family history of psychiatric illness, donors are only allowed to donate blood if they are not currently on medication and have no chronic illness. The remaining controls were recruited from the local population and from hospital staff. These controls were briefly screened by interview to exclude anyone currently on medication or with a history of treatment for psychiatric illness.

2.1.2. SNP Selection

SNP genotype data from 30 CEPH trios, 100 kb upstream and downstream of the PI4K2B genomic region (24,745,440–24,986,687 bp, NCBI build 35) from HapMap Phase II (January 2006) (http://www.hapmap.org) was uploaded to Haploview version 2.1.4. Association analysis was performed separately on bipolar disorder and schizophrenia cases with CoCaphase 2.4 (Dudbridge, 2003), using a sliding-windows approach to test all haplotypes of two marker length. Rare haplotypes with a frequency < 0.05 in both cases and controls were clumped together. Permutation analysis was also performed using CoCaphase.

2.2. Expression analysis

2.2.1. DNA samples

Lymphoblastoid cell lines from members of the large Scottish family were grown under standardised conditions, following standard protocols. All cell lines were subjected to the same cell culture and experimental conditions. Genomic DNA (gDNA) and RNA were prepared by the DNeasy Tissue Kit (Qiagen) and RNeasy Mini Kit (Qiagen) respectively. mRNA was reverse transcribed to cDNA with First Strand cDNA Kit (Roche) using random primers. “Quant-IT PicoGreen dsDNA Reagent and Kit” (Molecular Probes) was used to quantify DNA.

2.2.2. Allelic imbalance assay

rs313548 and rs313567 were available as pre-designed Taqman SNP genotyping assays (c_764549, c_764538, respectively) while rs6834255 was a custom designed Taqman SNP genotyping Assay (ABI). A standard curve of dilutions from homozygous lymphoblastoid cell line samples was prepared to evaluate the contribution of each allele in the heterozygote samples; genomic DNA prepared from two homozygote samples (5 ng/μl), as previously published (Pastinen et al., 2004). Ten microgram of mixed gDNA was assessed in a total volume of 5 μl, 2 μl gDNA, 0.25 μl Taqman SNP Genotyping Assay, 2.5 μl Taqman Universal PCR Master Mix. Each homozygote mix was assayed in quadruplicate. A standard curve (linear regression line) was established for the LOG of the fluorescent intensity ratio (FAM/VIC) versus the log of the allele ratio, i.e. the LOG2 ratio of the dilution of each homozygote (90:10 = LOG2 Ratio is 3.147), as previously published (Lo et al., 2003). For the heterozygote DNA samples, 4 ng cDNA or 10 ng gDNA was amplified; 2 μl cDNA (2 ng/μl) or 2 μl gDNA (5 ng/μl), 0.25 μl Taqman SNP Genotyping Assay, 2.5 μl Taqman® Universal PCR Master Mix, 0.25 μl dH2O. Each sample was prepared in quadruplicate and each assay was performed in triplicate from the same RNA preparation. The standard assay was performed in the ABI PRISM 7900HT sequence detection system (Applied Biosystems). From the endpoint read, the ratio of the fluorescence reading from the FAM™ reporter dye and VIC™ reporter dye was calculated. cDNA values were calculated by the cDNA/gDNA ratio from the mean value of DNA from the same individual.

2.2.3. Quantitative immunoblotting

The Western blotting procedure was performed on 5 μg protein lysates using NuPAGE® Electrophoresis System, as per manufacturer’s instructions with 17-well 4–12% Bis–Tris gels. Densitometry analysis was performed using ImageJ v 1.37 (Abramoff et al., 2004) to quantify the immunoreactive protein in each lane.

3. Results

3.1. Case-control association study

Fig. 1 shows sliding-window analysis of two-SNP haplotypes where two haplotypes emerged as significant at the global level
in the schizophrenia sample: rs17408391–rs10939038 (global $P = 0.005$, permuted global $P = 0.039$, SE:0.006) and rs10939038–rs3756207 (global $P = 0.01$, permuted global $P > 0.05$). Supplementary Table 2 shows the significant individual haplotype structures and corresponding $P$-values for these global haplotypes. Haplotype rs17408391–rs10939038 spans from LD block 1 to LD block 2, while haplotype rs10939038–rs3756207 falls within LD block 2 as illustrated in Fig. 1. Analysis at the single-marker level showed the only significant single-marker association less than the nominal significant level ($P = 0.05$) was rs10939038 in the schizophrenia cases ($P = 0.006$), which was previously reported (Christoforou et al., 2007) (data not shown). This association withstood the gene-wide permutation testing (1000 simulations) performed for this study (permuted $P = 0.015$, standard error (SE) = 0.0038). No association was detected in either bipolar disorder or schizophrenia at the single-marker level (all single marker $P$-values $> 0.05$) for the seven additional SNPs, which were selected to increase coverage of the PI4K2B region.

3.2. Expression studies

PI4K2B expression was measured at the RNA and protein level in lymphoblastoid cell lines from members of a large Scottish family. Certain members of the family have a defined haplotype on chromosome 4p15–p16, referred to as “the linked haplotype” that segregates with the majority of cases of bipolar disorder and recurrent major depression, as described previously (Le Hellard et al., 2007). RNA expression of PI4K2B was assessed in lymphoblastoid cell lines derived from the large Scottish family: Twelve samples with a “linked haplotype” and a psychiatric diagnosis [bipolar disorder ($n = 4$), recurrent major depression ($n = 4$), no symptoms ($n = 4$)] and founder individuals as controls ($n = 4$). Fig. 3 shows no evidence for a PI4K2B protein expression difference between linked haplotype carriers and controls in five replicate western blot experiments ($t$-test $P > 0.1$).

4. Discussion

PI4K2B was a worthy candidate gene for bipolar disorder in many respects. Positional evidence from linkage and association analyses have implicated this genomic region on chromosome 4p15–p16. Genetic evidence has also suggested other members of the phosphoinositide signalling pathway as susceptibility factors for bipolar disorder, schizophrenia and recurrent major depression (Kato, 2007) and components of the phosphoinositide pathway are inhibited by lithium, a therapeutic agent in bipolar disorder (Berridge et al., 1989). Indeed a recent consortium has been initiated to investigate all genes involved in the lithium pathway as candidate genes for psychiatric illness (Schulze et al., in

![Fig. 1](image-url) Distribution of global haplotype $P$-values from two-marker sliding window haplotype analysis in PI4K2B region. The x-axis is the chromosome 4 physical position in base pairs (bp) according to the human genome map of UCSC May 2004, NCBI build 35. The y-axis is the $P$-values on a $-\log$ scale. The results are shown for bipolar disorder in grey and schizophrenia in black. The nominal significance threshold is indicated with a dashed horizontal line at $P = 0.05$. The LD blocks are indicated by a bracket. The LD map of the region was defined by solid spine of LD ($D’ > 0.8$) using HapMap CEU trios downloaded on 7th February 2006, phase II b125. The position of genes in this region PI4K2B and SLA/LP are denoted with black arrows. The markers underlined are the follow-up markers specific to this present study ($n = 7$) and those not underlined were genotyped previously ($n = 4$) (Christoforou et al., 2007). The $P$-value for the first two markers was the same for both bipolar disorder and schizophrenia and overlap so cannot be seen.
press) (www.ConLiGen.org). Our study contributes to the genetic basis of psychiatric illness research by adopting a candidate gene study with two approaches; (i) an association study in 368 bipolar disorder, 386 schizophrenia and 458 Scottish participants and (ii) an expression study in lymphoblastoid cell lines from bipolar disorder and recurrent major depression members of a large Scottish family.

This study identified association between a haplotype in PI4K2B, which withstood gene-wide permutation testing, and schizophrenia, but not bipolar disorder. This improved haplotype association,
relative to the original single-marker finding, may better tag the actual susceptibility variant and thus narrow the target region. If replicated, the association results may reflect association with any feature within the large >240 kb genomic region investigated, in particular PI4KB or a neighbouring gene SLC/LP. Previous evaluation of population structure showed no evidence of population stratification in the control group, suggesting that this is unlikely to be the cause of any spurious association due to population stratification (Christoforou et al., 2007).

This study of PI4KB expression levels has shown no difference in lymphoblastoid cell line samples from bipolar disorder family members with the “linked haplotype” and those without. This was demonstrated at the allele-specific level by Taqman assays and at the protein level by quantitative immunoblotting techniques. The advantage of the Taqman method was the sensitivity obtained by comparing the linked haplotype to a series of different control alleles within the one family, using a well-validated method (Bakker et al., 2007; Pastinen et al., 2004). This method could reveal the presence of cis-acting regulatory variants, which may contribute to susceptibility for bipolar disorder. Cis-acting variation has been reported to account for 25–35% of inter-individual differences in gene expression throughout the human genome (Pastinen and Hudson, 2004). Three PI4KB SNPs were used to measure gene expression levels, one of which was an intronic SNP to measure heteronuclear RNA as previously described (Pastinen et al., 2004). Initially, standard curves of homozygote gDNA dilutions were created, to look for a deviation from the expected 1:1 allelic ratio in cDNA. Despite optimisation attempts, the standard curves did not achieve the required sensitivity to detect small differences. However, the standard curves were useful to show that a gross deviation in allele-specific expression was not present. A second method, which compared expression in cDNA to that seen in gDNA from heterozygous samples, proved more sensitive. Indeed, in the future it may be useful to investigate lymphoblastoid cell lines from schizophrenia patients for PI4KB expression differences due to the above association study evidence.

The limitations of this expression study are the sensitivity of the technical procedures, the reduced power from the limited number of heterozygote family members with viable lymphoblastoid cell lines available and whether lymphoblastoid cell lines effectively model pathogenic processes in the brain (Gladkevich et al., 2004; Tsuang et al., 2005). Studies have shown that whole blood does share significant gene expression similarities with multiple central nervous system tissues (Sullivan et al., 2006). There is also evidence to suggest that gene expression profiles and functional effects in blood lymphocytes do correlate with psychiatric illness (Gladkevich et al., 2004; Iwamoto et al., 2004; Marazziti et al., 2006; Tsuang et al., 2005; Vawter et al., 2004).

This study showed that there was no direct evidence for a role of PI4KB in susceptibility to bipolar disorder from expression studies in lymphoblastoid cell lines. Nevertheless, this candidate gene still merits further investigation to assess its potential role in psychiatric illness, because of the significant case-control association study result that withstand permutation testing.

Conflict of interest

All authors declare that they have no conflicts of interest.

Contributors

Lorna M. Houlihan, Kathryn L. Evans and David J. Porteous designed the study and wrote the protocol. Lorna M. Houlihan managed the literature searches, undertook the statistical analysis and performed the expression experiments. Andrea Christoforou helped in design and interpretation of the association study. Margaret I. Arbuckle, Helen S. Torrance and Susan M. Anderson helped with sample preparation and molecular biology techniques. Douglas H. Blackwood and Walter J. Muir ascertained the samples. Lorna M. Houlihan wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Role of funding source

Funding for this study was provided by the Wellcome Trust Grant 072874; the Wellcome Trust had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Acknowledgements

This study was supported by the Wellcome Trust. We would like to thank the patients and family for their participation in this study; Dr. Philippa Thomson, Dr. Stephanie Le Hallard and Euan Adie for help with the association study; Dr. Jennifer Chubb, Dr. Shaun Mackie and John Beekman for technical assistance; the Wellcome Trust Clinical Research Facility Genetics Core for help with sample preparation and genotyping; Dr. Shane Minogue for the antibody and positive control; Dr. Tamas Balla for the PI4KB plasmid.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jpsychires.2009.05.004.

References


Wei YJ, Sun HQ, Yamamoto M, Wlodarski P, Kunii K, Martinez M, et al. Type II phosphatidylinositol 4-kinase beta is a cytosolic and peripheral membrane protein that is recruited to the plasma membrane and activated by Rac-GTP. J Biol Chem 2002;277:46586–93.